0
Black Diamond Therapeutics, Inc. Banner Image

Black Diamond Therapeutics, Inc.

  • Ticker BDTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Black Diamond Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technologyMore platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine.
REPORT RATINGS
4.8 / 5.0 (98)

Black Diamond Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 98 reviews.

Black Diamond Therapeutics, Inc.

Most Recent Annual Report

Black Diamond Therapeutics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Black Diamond Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!